Pietro Delcanale

Dr. Pietro Delcanale


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2017 in Nature
Verified
Journal Article
Closed access
PDF file
RORoger Oria
Roger Oria
TWTina Wiegand
Tina Wiegand
JEJorge Escribano
Jorge Escribano
AEAlberto Elosegui-Artola
Alberto Elosegui-Artola
JUJuan Jose Uriarte
Juan Jose Uriarte
PRPere Roca-Cusachs
Pere Roca-Cusachs

24 January 2019 in Nature Reviews Chemistry
Verified
Journal Article
Closed access
PDF file
SPSilvia Pujals
Silvia Pujals
NFNatalia Feiner-Gracia
Natalia Feiner-Gracia
PDPietro Delcanale
Pietro Delcanale
Ilja VoetsIlja Voets
Ilja Voets
LALorenzo Albertazzi
Lorenzo Albertazzi

26 July 2018 in ACS Nano
Verified
Journal Article
Closed access
PDPietro Delcanale
Pietro Delcanale
BMBernat Miret-Ontiveros
Bernat Miret-Ontiveros
MRMaria Arista Romero
Maria Arista Romero
SRSílvia Pujals Riatos
Sílvia Pujals Riatos
LALorenzo Albertazzi
Lorenzo Albertazzi

1 January 2015 in Journal of Dairy Science
Verified
Journal Article
Closed access
BRBeatriz Rodríguez-Amigo
Beatriz Rodríguez-Amigo
PDPietro Delcanale
Pietro Delcanale
GRGabriel Rotger
Gabriel Rotger
JJJordi Juarez-Jimenez
Jordi Juarez-Jimenez
Stefania AbbruzzettiStefania Abbruzzetti
Stefania Abbruzzetti
CVCristiano Viappiani
Cristiano Viappiani
Using a combination of molecular modeling and spectroscopic experiments, the naturally occurring, pharmacologically active hypericin compound is shown to form a stable complex with the dimeric form of β-lactoglobulin (β-LG). Binding is predicted to occur at the narrowest cleft found at the interface between monomers in the dimeric β-LG. The complex is able to preserve the fluorescence and singlet oxygen photosensitizing properties of the dye. The equilibrium constant for hypericin binding has been determined as Ka=1.40±0.07µM(-1), equivalent to a dissociation constant, Kd=0.71±0.03µM. The complex is active against Staphylococcus aureus bacteria. Overall, the results are encouraging for pursuing the potential application of the complex between hypericin and β-LG as a nanodevice with bactericidal properties for disinfection.

23 October 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PDPietro Delcanale
Pietro Delcanale
FPFrancesca Pennacchietti
Francesca Pennacchietti
GMGiulio Maestrini
Giulio Maestrini
BRBeatriz Rodríguez-Amigo
Beatriz Rodríguez-Amigo
PBPaolo Bianchini
Paolo Bianchini
CVCristiano Viappiani
Cristiano Viappiani
Antibacterial treatments based on photosensitized production of reactive oxygen species is a promising approach to address local microbial infections. Given the small size of bacterial cells, identification of the sites of binding of the photosensitizing molecules is a difficult issue to address with conventional microscopy. We show that the excited state properties of the naturally occurring photosensitizer hypericin can be exploited to perform STED microscopy on bacteria incubated with the complex between hypericin and apomyoglobin, a self-assembled nanostructure that confers very good bioavailability to the photosensitizer. Hypericin fluorescence is mostly localized at the bacterial wall and accumulates at the polar regions of the cell and at sites of cell wall growth. While these features are shared by Gram-negative and Gram-positive bacteria, only the latter are effectively photoinactivated by light exposure.

18 March 2022 in ACS Applied Materials & Interfaces
Verified
Journal Article
Open access
PDPietro Delcanale
Pietro Delcanale
EUEleonora Uriati
Eleonora Uriati
MMMatteo Mariangeli
Matteo Mariangeli
AMAndrea Mussini
Andrea Mussini
AMAna Moreno
Ana Moreno
CVCristiano Viappiani
Cristiano Viappiani
Hypericin is a photosensitizing drug that is active against membrane-enveloped viruses and therefore constitutes a promising candidate for the treatment of SARS-CoV-2 infections. The antiviral efficacy of hypericin is largely determined by its affinity toward viral components and by the number of active molecules loaded on single viruses. Here we use an experimental approach to follow the interaction of hypericin with SARS-CoV-2, and we evaluate its antiviral efficacy, both in the dark and upon photoactivation. Binding to viral particles is directly visualized with fluorescence microscopy, and a strong affinity for the viral particles, most likely for the viral envelope, is measured spectroscopically. The loading of a maximum of approximately 30 molecules per viral particle is estimated, despite with marked heterogeneity among particles. Because of this interaction, nanomolar concentrations of photoactivated hypericin substantially reduce virus infectivity on Vero E6 cells, but a partial effect is also observed in dark conditions, suggesting multiple mechanisms of action for this drug.